Tavapadon

AbbVie announced positive phase 3 TEMPO-2 trial results for tavapadon, a Parkinson’s disease candidate, meeting primary and secondary endpoints. The company plans to submit a new drug application to the FDA in 2025. AbbVie acquired tavapadon through its $8.7bn Cerevel Therapeutics acquisition.

Clene receives FDA guidance on accelerated approval for CNM-Au8 in ALS, planning biomarker analysis. uniQure aligns with FDA on accelerated approval pathway for AMT-130 in Huntington disease. AbbVie's tavapadon meets primary and secondary endpoints in early Parkinson disease phase 3 trial.

Parkinson's disease market to grow at 5.8% CAGR (2020-2034) due to advancements in diagnostics, increased awareness, and a rising number of cases. Emerging therapies like Supernus/Britannia's SPN-830, AbbVie's tavapadon, and Pharma Two B's P2B001 could significantly impact market dynamics. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size (2020-2034) for 7MM.

AbbVie's phase 3 TEMPO-2 trial showed tavapadon met primary and secondary endpoints in early Parkinson disease, with significant reductions in MDS-UPDRS Parts II and III scores. AbbVie plans to submit full results for presentation and the new drug application to the FDA in 2025.

BenevolentAI co-founder Kenneth Mulvaney announces restructuring to return to 'techbio' roots, including layoffs and delisting from Euronext Amsterdam. Tasca Therapeutics raises $52M in Series A funding for cancer drug development. Eli Lilly's board approves $15B stock buyback and 15% dividend increase. AbbVie's Parkinson's drug tavapadon succeeds in Phase 3 trial, prompting approval filing plans. Biogen appoints Tim Power as head of investor relations.

AbbVie, a $310B pharmaceutical giant, acquired Aliada Therapeutics, gaining ALIA-1758, a Phase 1 Alzheimer's therapy, and a novel CNS drug delivery platform. This move strengthens AbbVie's neuroscience pipeline, aiming to address Alzheimer's, a growing public health challenge. AbbVie's strong financials support its R&D efforts, including this strategic acquisition.

AbbVie's Phase 3 TEMPO-2 trial of tavapadon met primary endpoint with significant improvement in MDS-UPDRS Parts II and III scores at week 26, showing a reduction of -10.3 vs. -1.2 for placebo. Tavapadon, a D1/D5 partial agonist, is under investigation as a once-daily treatment for Parkinson's disease. AbbVie plans to submit an NDA to the FDA in 2025.

Researchers identified 13 proteins predicting brain aging speed; midlife anxiety often precedes dementia; tavapadon improved Parkinson's symptoms; neflamapimod failed in dementia with Lewy bodies; cortical sulcus neurodegeneration linked to CTE; ALS/cancer patients more likely to choose assisted dying; former soccer players at higher dementia risk; diverse brain cells contribute to Alzheimer's neuroinflammation; media highlighted Alzheimer's and Parkinson's stories.

The Parkinson's disease market is expected to grow significantly, reaching USD 6.2 billion by 2034, driven by advancements in diagnostics, disease awareness, and emerging therapies. Key therapies in development include ND0612, tavapadon, P2B001, BIIB122/DNL151, Buntanetap, Solengepras, and Minzasolmin. These therapies aim to improve motor function, manage symptoms, and potentially slow disease progression.

AbbVie's Phase III TEMPO-2 trial of tavapadon, a D1/D5 partial agonist for early-stage Parkinson’s disease, met its primary endpoint, showing significant motor function improvements. The trial also achieved a key secondary endpoint, indicating meaningful daily living motor experiences improvement. AbbVie plans to submit an NDA to the FDA next year, with tavapadon's safety profile consistent with previous studies.